JPWO2022082066A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022082066A5 JPWO2022082066A5 JP2023548537A JP2023548537A JPWO2022082066A5 JP WO2022082066 A5 JPWO2022082066 A5 JP WO2022082066A5 JP 2023548537 A JP2023548537 A JP 2023548537A JP 2023548537 A JP2023548537 A JP 2023548537A JP WO2022082066 A5 JPWO2022082066 A5 JP WO2022082066A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 91
- 239000011230 binding agent Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 31
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 29
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 29
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 29
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 29
- 238000009169 immunotherapy Methods 0.000 claims description 29
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 239000002254 cytotoxic agent Substances 0.000 claims description 20
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 20
- 238000002512 chemotherapy Methods 0.000 claims description 18
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 8
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 8
- 229940121420 cemiplimab Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 102000048776 human CD274 Human genes 0.000 claims description 8
- 102000043321 human CTLA4 Human genes 0.000 claims description 8
- 102000048362 human PDCD1 Human genes 0.000 claims description 8
- 229960005386 ipilimumab Drugs 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 7
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 229930195731 calicheamicin Natural products 0.000 claims description 5
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical group C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 claims description 4
- 229950009429 exatecan Drugs 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 102000057939 human CSPG4 Human genes 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002228 disulfide group Chemical group 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229920002704 polyhistidine Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 32
- 125000005647 linker group Chemical group 0.000 claims 16
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 241001529936 Murinae Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093255P | 2020-10-18 | 2020-10-18 | |
| US63/093,255 | 2020-10-18 | ||
| PCT/US2021/055311 WO2022082066A1 (en) | 2020-10-18 | 2021-10-15 | Anti-cspg4 binding agents, conjugates thereof and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546293A JP2023546293A (ja) | 2023-11-01 |
| JP2023546293A5 JP2023546293A5 (https=) | 2024-10-16 |
| JPWO2022082066A5 true JPWO2022082066A5 (https=) | 2024-10-16 |
Family
ID=78709534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548537A Pending JP2023546293A (ja) | 2020-10-18 | 2021-10-15 | 抗ｃｓｐｇ４結合剤、そのコンジュゲートおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250213715A1 (https=) |
| EP (1) | EP4228704A1 (https=) |
| JP (1) | JP2023546293A (https=) |
| CN (1) | CN116782955A (https=) |
| CA (1) | CA3195865A1 (https=) |
| WO (1) | WO2022082066A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836541B (zh) * | 2022-05-23 | 2026-02-17 | 中国药科大学 | 一种利用尿液微囊泡蛋白作为肾癌诊断标志物的应用 |
| CN120417935A (zh) * | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004213053C1 (en) * | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| NZ565075A (en) * | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| BR112014004168A2 (pt) * | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| WO2015012904A2 (en) * | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| RU2015140921A (ru) * | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Антитела к mcsp |
-
2021
- 2021-10-15 JP JP2023548537A patent/JP2023546293A/ja active Pending
- 2021-10-15 WO PCT/US2021/055311 patent/WO2022082066A1/en not_active Ceased
- 2021-10-15 US US18/247,628 patent/US20250213715A1/en active Pending
- 2021-10-15 EP EP21811176.3A patent/EP4228704A1/en active Pending
- 2021-10-15 CN CN202180078901.0A patent/CN116782955A/zh active Pending
- 2021-10-15 CA CA3195865A patent/CA3195865A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| EP3307274B1 (en) | Anti-cd123 antibodies and conjugates thereof | |
| AU2012235817B2 (en) | Antibody-drug conjugates | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| US20180092984A1 (en) | Cd48 antibodies and conjugates thereof | |
| JP2012522513A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2015509947A5 (https=) | ||
| JP2015533781A5 (https=) | ||
| JP2018509146A (ja) | Ｆｌｔ３タンパク質に結合する抗体薬物複合体（ａｄｃ） | |
| JPWO2021213434A5 (https=) | ||
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| JP2023036874A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 | |
| EP4484446A1 (en) | Antibody, and drug conjugate and use thereof | |
| US20250090677A1 (en) | Anti-cdh6 antibodies and antibody-drug conjugates thereof | |
| AU2014342610A1 (en) | Anti-EFNA4 antibody-drug conjugates | |
| JPWO2022082066A5 (https=) | ||
| JPWO2023092099A5 (https=) | ||
| US20250197501A1 (en) | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers | |
| EP4344707A1 (en) | New anti-nectin-4 antibody drug conjugates | |
| JP2025509338A (ja) | Ｒｏｒ１標的結合分子とその使用 | |
| WO2025054621A1 (en) | Anti-camptothecin antibodies and antibody fragments | |
| RU2021119682A (ru) | Антитела против клаудина и их применение | |
| IL318911A (en) | Humanized antibodies against NECTIN-4 and their drug conjugates | |
| RU2025134256A (ru) | Конъюгат антитела к pdl1 и лекарственного средства и применение |